secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001579428-25-000007
Event type: litigation
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome receives ANDA Paragraph IV notice from Apotex for generic Symbravo
-------------------------------------------------------------------------

- Apotex filed an ANDA seeking FDA approval to market a generic version of Symbravo (meloxicam-rizatriptan benzoate).
- Paragraph IV certification notice received August 19, 2025; Axsame plans to respond in due course.
- If Axsame sues within 45 days, a 30-month stay could delay generic approval.
- Generic competition threatens Symbravo revenue, which is Axsome's key commercial product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000157942825000007/0001579428-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000157942825000007/axsm-20250819.htm
  HTML page:      https://secwatch.observer/filing/0001579428-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer